LFWD — Lifeward Ltd.

Summary of Lifeward, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $22 million for FY 2025, down 14% from $25.7 million in 2024.
• Revenue Breakdown:
  • ReWalk personal exoskeleton: $8.5 million (flat year-over-year).
  • MyoCycle FES bike: $600,000 (down 50%).
  • AlterG products: $12.9 million (down 18%).
• Gross Profit: Increased to $8.4 million (38.2% of revenue) from $8.2 million (32% of revenue) in 2024.
• Operating Expenses: Decreased by 25% to $28.1 million.
• Operating Loss: Narrowed by 33% to $19.7 million.
• Net Loss: Narrowed by 31% to $19.9 million.
• Cash Position: $2.2 million in unrestricted cash as of December 31, 2025.

2. Strategic Updates and Business Highlights

• Lifeward is transitioning into a diversified biomedical innovation company, focusing on neuro rehabilitation, robotic technologies, and metabolic therapeutics.
• Strategic partnership with Oramed approved, providing access to capital and enhancing growth initiatives.
• Acquisition of Skelable’s technology for a powered upper extremity orthotic system, aimed at stroke rehabilitation, is expected to expand Lifeward's market presence.
• Progress in reimbursement coverage, with significant wins from major Medicare Advantage insurers, enhancing patient access to ReWalk systems.

3. Forward Guidance and Outlook

• No specific revenue guidance provided due to ongoing transformations and pending strategic agreements.
• Management remains optimistic about achieving cash flow positivity in the near future, supported by improved operational efficiencies and a growing product pipeline.
• Anticipation of increased sales and market penetration as new commercial strategies mature.

4. Bad News, Challenges, or Points of Concern

• Revenue decline attributed to a transition in sales and distribution strategy, which may take time to yield results.
• AlterG sales affected by a distributor’s inventory dynamics, leading to lower year-over-year sales.
• Overall revenue performance fell short of earlier expectations, indicating potential execution challenges.
• The company is still in the early stages of integrating its diversified product offerings, which may pose risks in operational focus and resource allocation.

5. Notable Q&A Insights

• Management emphasized the importance of leveraging existing commercial infrastructure for the new oral insulin product from Oramed, while maintaining focus on core business operations.
• The upper extremity robotic assistance technology is expected to enter the market within 18-24 months, with a streamlined regulatory process anticipated.
• Concerns were raised about the diversification strategy, with management reassuring investors of a disciplined approach to commercialization and reimbursement pathways.
• The growth in unit sales (22% year-over-year) was highlighted as a positive trend, despite overall revenue challenges, indicating strong underlying demand for ReWalk systems.

Overall, Lifeward is navigating through a significant transformation phase, focusing on strategic partnerships and product innovation while addressing revenue challenges and operational restructuring.